In collaboration with researchers at the UTHSC College of Pharmacy and grant support from Genentech, Tennessee Pharmacy Association would like to share an opportunity for community-based/outpatient pharmacies to enroll in a study investigating pharmacists’ management of influenza using point-of-care testing. Click here to learn more and enroll.
Also in Tennessee, updated versions of the Preferred Drug List (PDL), criteria PDL and interim criteria PDL are available, as well as the monthly provider notice for October 2022. Below is a summary of the updates:
- The following agents will be added to the PDL as non-preferred:
- Adlarity, Bylvay, Epsolay, Livmarli, Livtencity, Norliqva, Opzelura, Rezurock, Skytrofa, Tavneos, Tarpeyo, Triumeq PD
- Clinical criteria and/or quantity limits will be updated for the following agents:
- Nubeqa, Nucala, Olumiant, Skyrizi
- The following agents will be added to the interim criteria PDL:
- Radicava ORS, Vtama
- Proventil HFA will be moved to preferred on the PDL in response to marketing discontinuation of Proair HFA
Updates to clinical criteria/quantity limits from the Q3 PAC meeting will also became effective on October 1 and were summarized in the September provider notice.
These documents are available on the TennCare website.
For more information, contact NACDS’ Leigh Knotts at 803-243-7207.